Drug
Wockhardt’s Zaynich gains CDSCO and FDA approval
Zaynich, a new broad-spectrum antibiotic by Wockhardt, was approved by CDSCO on May 27, preceding its FDA nod. Indicated for resistant Gram-positive infections, including refractory odontogenic abscesses. Standard adult dosing in dentistry: 600 mg twice daily for 10–14 days. Pending commercial launch in India, it offers a novel treatment for dental infections unresponsive to first-line agents.
Source: Biotecnika
19 Nov 2026 · DentalSync AI — global BDS career platform